EMA Authorised: Vydura (rimegepant) — Pfizer Europe MA EEIG

View source ↗

Summary

The European Medicines Agency has authorised Vydura (rimegepant) for migraine disorders, with Pfizer Europe MA EEIG as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Vydura (rimegepant)

Snippet

Status: Authorised. Therapeutic area: Migraine Disorders. MAH: Pfizer Europe MA EEIG. Decision date: 15/01/2026